V. Préat
Biomaterials · 2009–2017
A researcher in the Science corpus: 6 papers; trusts 6 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Biomaterials — 66 citations into it; #993 of 2,152 by trust here, #879 by citations
- Molecular Biology — 58 citations into it; #9,841 of 17,773 by trust here, #6,475 by citations
- Biomedical Engineering — 32 citations into it; #5,872 of 10,734 by trust here, #4,781 by citations
- Pharmaceutical Science — 23 citations into it
- Oncology — 17 citations into it
- Immunology — 12 citations into it
- Cancer Research — 8 citations into it
- Immunology and Allergy — 5 citations into it
Whom V. Préat trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts V. Préat overall
Papers from V. Préat's perspective
Ordered by how strongly the researchers V. Préat trusts endorse each paper. Same corpus, a different order for every researcher.
- Molecular mechanisms and clinical applications of angiogenesis (Nature)
- High interstitial fluid pressure — an obstacle in cancer therapy (Nature Reviews. Cancer)
- Polymer conjugates as anticancer nanomedicines (Nature Reviews. Cancer)
- Active targeting schemes for nanoparticle systems in cancer therapeutics. (Advanced Drug Delivery Reviews)
- Ligand-targeted therapeutics in anticancer therapy (Nature Reviews. Cancer)
- Strategies in the design of nanoparticles for therapeutic applications (Nature reviews. Drug discovery)
- Exploiting lymphatic transport and complement activation in nanoparticle vaccines (Nature Biotechnology)
- Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging (Advanced Drug Delivery Reviews)
- Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. (Journal of Clinical Oncology)
- Nanoparticles in cancer therapy and diagnosis. (Advanced Drug Delivery Reviews)
Their papers
- To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010) — 2,572 citations
- Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. (2009) — 608 citations
- PLGA-based nanoparticles: an overview of biomedical applications. (2012) — 3,515 citations
- RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. (2012) — 898 citations
- Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures (2017) — 315 citations
- Nanostructured lipid carriers: Promising drug delivery systems for future clinics. (2016) — 615 citations